A Phase 2 interventional study of Mizagliflozin in Postbariatric Hypoglycemia, sponsored by Vogenx, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-25.
Sponsored by Vogenx, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 294 studies in Hypoglycemia with a site in United States — 36 open to participants now, 49 under way, 5 of them phase 3. Hypoglycemia · United States.
Among the 294 studies in Hypoglycemia with a site in United States, this one is the 193rd largest by enrollment of the 239 interventional ones that give a count, is one of 12 that started in 2022, is one of 38 in phase 2, and was the 246th registered.
706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.
Browse Hypoglycemia studies →36 of the 294 studies in Hypoglycemia with a site in United States are open now. Recruiting first, the newest first:
Vogenx, Inc. · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 65+
Indiana University · Sites in United States
Ages 7–25
Joslin Diabetes Center · Sites in United States
Ages 18–70 · Healthy volunteers
Indiana University · Sites in United States
Ages 12–19
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
294 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 54 · Phase 2 69 · Phase 3 35 · Phase 4 12
First in 1991; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 28 across 534 interventional studies indexed under Hypoglycemia.
Median enrollment 24 across the 239 interventional studies, 71 across the 48 observational. Of the 219 that completed or were terminated, 102 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 294 have an industry lead sponsor. The 10 most frequent:
Vogenx, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Vogenx, Inc. has 3 studies filed under Hypoglycemia — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypoglycemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06881992Phase 3RezoluteA Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | 2027-09 |
| NCT07215312Eli Lilly and CompanyA Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | 2026-11 |
| NCT04428723Joslin Diabetes CenterMechanisms of Hypoglycemia in Patients Without Diabetes | 2026-12 |
| NCT05762107Zucara Therapeutics Inc.A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | 2026-12 |
| NCT06893341Indiana UniversityMonitoring Exhaled Breath to Noninvasively Detect Glycemic Events | 2026-12-01 |
Add all 18 to your calendar (.ics) → With an account.
Among the 294 studies in Hypoglycemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).
This is a Phase 2 randomized, sequential crossover single ascending dose study in PBH subjects to determine the effect of two mizagliflozin formulations This study will examine single doses of mizagliflozin in either a liquid or encapsulated formulation. Subjects will be randomly assigned to one of two treatment arms. Safety, tolerability and pharmacodynamic response to mizagliflozin will be assessed in subjects during a mixed meal tolerance test (MMTT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive two separate single doses (Period 1 and Period 2) of encapsulated mizagliflozin
Drug: Mizagliflozin
Subjects will receive one dose of liquid formulation (Period 1), and one dose (optional) of encapsulated mizagliflozin (Period 2)
Drug: Mizagliflozin
Encapsulated or Liquid Formulation
Glucose Nadir After Mizagliflozin Dosing
Time course of glucose concentrations during MMTT
Time frame: 0-3 hours following liquid meal
9 participants were screened between September 2022 and January 2023. 7 participants at University of Colorado/Anschutz Medical Campus and 2 participants at Stanford.University
| Milestone | Treatment Arm A | Treatment Arm B |
|---|---|---|
| Started | 5 | 4 |
| Completed | 5 | 4 |
| Not completed | 0 | 0 |
Time course of glucose concentrations during MMTT
| mg/dL | Treatment Arm A | Treatment Arm B |
|---|---|---|
| 2.5 mg Capsule | 6.2 ± 14.8 | — |
| 5.0 mg Capsule | 4.0 ± 17.7 | — |
| 2.5 mg Liquid | — | 17.5 ± 30.5 |
| 10.0 mg Capsule | — | 31.5 ± 29.0 |
Collected over 34 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Arm A Period 1 (2.5 mg Capsule) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Treatment Arm A Period 2 (5.0 mg Capsule) | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Treatment Arm B Period 1 (2.5 mg Liquid Formulation) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Treatment Arm B Period 2 (10.0 mg Capsule) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | Treatment Arm A Period 1 (2.5 mg Capsule) | Treatment Arm A Period 2 (5.0 mg Capsule) | Treatment Arm B Period 1 (2.5 mg Liquid Formulation) | Treatment Arm B Period 2 (10.0 mg Capsule) |
|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 2/5 | 0/5 | 1/4 | 0/4 |
| NauseaGastrointestinal disorders | 2/5 | 0/5 | 1/4 | 1/4 |
| HypokalaemiaMetabolism and nutrition disorders | 2/5 | 0/5 | 0/4 | 0/4 |
| LeukopeniaBlood and lymphatic system disorders | 0/5 | 0/5 | 1/4 | 0/4 |
| Abdominal distensionGastrointestinal disorders | 1/5 | 0/5 | 0/4 | 1/4 |
| DiarrhoeaGastrointestinal disorders | 0/5 | 0/5 | 1/4 | 1/4 |
| HungerGeneral disorders | 0/5 | 0/5 | 1/4 | 0/4 |
| HeadacheNervous system disorders | 1/5 | 0/5 | 1/4 | 0/4 |
| VomitingGastrointestinal disorders | 1/5 | 0/5 | 0/4 | 0/4 |
| Infections and infestationsGeneral disorders | 0/5 | 1/5 | 0/4 | 0/4 |
| Age, Categorical(Participants) | Treatment Arm A | Treatment Arm B | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 8 |
| >=65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Treatment Arm A | Treatment Arm B | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Arm A | Treatment Arm B | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 4 | 2 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Arm A | Treatment Arm B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 4 | 3 | 7 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline MMTT (pharmacodynamic assessment for glucose and insulin)(Participants) | Treatment Arm A | Treatment Arm B | Total |
|---|---|---|---|
| Count of participants | 5 | 4 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2022 to primary completion in Feb 2023, 5 months.
Results were first posted in Jun 2024, 1 year 4 months after primary completion.
Of 24 phase 2 interventional studies under Hypoglycemia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mizagliflozin